BIOVF News and Press, Swedish Orphan Biovit Ord From 07/17/19

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2019 Earnings Conference Call July 17, 2019 03:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financial Officer Milan Zdravkovic - Head of Research & Development and Chief Medical Of...

The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2019 Q2 earnings Read more ...

Swedish Orphan Biovitrum AB (publ) ( OTCPK:BIOVF ): Q2 Non-GAAP EPS of SEK2.12; GAAP EPS of SEK1.70. More news on: Swedish Orphan Biovitrum AB (publ), Earnings news and commentary, Healthcare stocks news, Read more ...

STOCKHOLM , July 17, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the second quarter 2019. Total revenue was SEK 3,163 M (2,289), with 38 per cent revenue growth in the quarter compared with Q2 2018 (32 per cent at constant exc...

STOCKHOLM , July 16, 2019 /PRNewswire/ -- Sobi™ has established the Sobi Scientific Innovation Awards, with a focus on the future of haemophilia care, to recognise innovation and scientific excellence in haemophilia research. Entries will be assessed by an Adjudication Committee...

STOCKHOLM , July 8, 2019 /PRNewswire/ -- On 17 July, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the second quarter 2019. Financial analysts and media are invited to participate in a telephone conference, which will include a presentatio...

STOCKHOLM , June 18, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announces that new research demonstrating the effects of emapalumab in patients with macrophage activation syndrome (MAS), a form of secondary haemophagocytic lymphohistiocytosis (HLH)...

Swedish Orphan Biovitrum AB ( OTCPK:BIOVF ) has signed an agreement to acquire (from Novimmune's shareholders) a newly established company owning emapalumab and related assets (previously announced exclusive licence agreement with Novimmune will be superseded). More news on: Swedish Orph...

STOCKHOLM , June 12, 2019 /PRNewswire/ -- Intended reorganisation of R&D to increase focus and investment in late-stage development Plans to establish centres of excellence in Sweden and Switzerland The new focus of the R&D organisation would lead to annual savings of S...

STOCKHOLM , June 12, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI)   has signed an agreement to acquire, from Novimmune's shareholders, a newly established company owning emapalumab and related assets, giving Sobi access to world-class R&D ca...